Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients

Area of Science:

• Pulmonology
• Regenerative Medicine
• Virology

Background:

• COVID-19 poses a significant global health challenge, necessitating innovative therapeutic strategies for intensive care patients.
• Pneumocytes II are primary targets in early SARS-CoV-2 infection, leading to severe respiratory system damage.
• Mesenchymal stem cell (MSC) secretome, rich in growth factors, extracellular vesicles, and exosomes, has demonstrated efficacy in treating bleomycin-induced pulmonary injuries in murine models.

Discussion:

• The study proposes investigating MSC secretome as a potential therapeutic for critical COVID-19 patients.
• The rationale is based on MSC secretome's known regenerative properties for lung tissue.
• Emphasis is placed on producing MSC secretome under xenofree conditions to ensure safety and efficacy.

Key Insights:

• MSC secretome contains bioactive components like growth factors and extracellular vesicles beneficial for lung repair.
• Previous studies in murine models support the therapeutic potential of MSC secretome for pulmonary damage.
• The unique composition of MSC secretome suggests a novel approach for managing SARS-CoV-2-induced lung injury.

Outlook:

• Recommend testing and production of MSC secretome for clinical application in severe COVID-19.
• Explore xenofree production methods for MSC secretome to meet clinical standards.
• Investigate the specific mechanisms by which MSC secretome components exert therapeutic effects in SARS-CoV-2 infection.